Applied Therapeutics APLT

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    +$0.07 (+13.68%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Applied Therapeutics (APLT)
    Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $0.5724

    • Market Cap

      $66.60 Million

    • Price-Earnings Ratio

      -1.19

    • Total Outstanding Shares

      116.36 Million Shares

    • Total Employees

      37

    • Dividend

      No dividend

    • IPO Date

      May 13, 2019

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      545 fifth avenue, suite 1400, New york, NY, 10017

    • Homepage

      https://www.appliedtherapeutics.com

    Historical Stock Splits

    Execution DateSplit Amount
    No Historical Stock Splits

    Cash Flow Statement

    July 1, 2024 to September 30, 2024
    MetricValue
    Net Cash Flow From Operating Activities, Continuing$-23.33 Million
    Net Cash Flow, Continuing$0
    Net Cash Flow$0
    Net Cash Flow From Investing Activities, Continuing$23.33 Million
    Net Cash Flow From Investing Activities$23.33 Million
    Net Cash Flow From Financing Activities, Continuing$0

    Income Statement

    July 1, 2024 to September 30, 2024
    MetricValue
    Net Income/Loss Attributable To Noncontrolling Interest$0
    Basic Earnings Per Share$-0.48
    Operating Income/Loss$-29.74 Million
    Other Operating Expenses$15.04 Million
    Nonoperating Income/Loss$-38.85 Million
    Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0

    Comprehensive Income

    July 1, 2024 to September 30, 2024
    MetricValue
    Comprehensive Income/Loss$-68.59 Million
    Other Comprehensive Income/Loss$-68.59 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Comprehensive Income/Loss Attributable To Parent$-68.59 Million

    Balance Sheet

    July 1, 2024 to September 30, 2024
    MetricValue
    Liabilities$100.67 Million
    Equity$5.89 Million
    Other Current Liabilities$96.13 Million
    Noncurrent Liabilities$1.71 Million
    Assets$106.57 Million
    Equity Attributable To Parent$5.89 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about APLT from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.